DSR 6434
DSR 6434 性质
| 密度 | 1.283±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:145.03(最大浓度 mg/mL);362.12(最大浓度 mM) |
| 形态 | 固体 |
| 酸度系数(pKa) | 10.22±0.20(Predicted) |
| 颜色 | 浅黄至黄色 |
DSR 6434 用途与合成方法
|
TLR7 7.2 nM (EC 50 , Human) |
TLR7 4.6 nM (EC 50 , Mice) |
To assess the specificity of DSR-6434 toward TLR7, an NF-κB-driven reporter assay is performed in HEK293 cells engineered to express either hTLR7, TLR8 or TLR9. In this assay, successful binding of DSR-6434 to the specific receptor leads to NF-κB activation. DSR-6434 is capable of stimulating reporter gene activity only in HEK293 cells expressing hTLR7 and not in HEK293 cells expressing the structurally similar hTLR8 or hTLR9.
DSR-6434 treatment (Compound 20; 0.1-1 mg/kg; intravenous injection; biweekly; for 4 weeks; B6C3F1 mice) suppresses the lung metastasis significantly, 78% inhibition at 0.1 mg/kg dosing (with no tumor metastasis at the 1 mg/kg group).
| Animal Model: | B6C3F1 mice injected with HM-1 ovarian cancer cells |
| Dosage: | 0.1 mg/kg, 1 mg/kg |
| Administration: | Intravenous injection; biweekly; for 4 weeks |
| Result: | Suppressed the lung metastasis significantly, 78% inhibition was seen at 0.1 mg/kg dosing (with no tumor metastasis at the 1 mg/kg group). |
DSR 6434 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-110120 | 1 mg | 495 | ||
| 2024-04-30 | HY-110120 | DSR 6434 | 1059070-10-8 | 5mg | 1300 |
